Cold agglutinin disease following allogeneic bone marrow transplantation.
We describe a case of cold agglutinin disease (CAD) following allogeneic bone marrow transplantation. This 36-year-old male developed CAD 3 weeks after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Cyclosporin A and methotrexate had been administered to prevent graft-versus-host disease. Other agents administered included cytomegalovirus hyperimmune globulin and recombinant human G-CSF. Pericarditis preceded the development of CAD. The characterization of cold agglutinin (CA) was monoclonal IgM-kappa with anti-Pr antigen specificity, probably derived from the engrafted donor lymphocytes. The administration of prednisolone led to transient improvement. The CA titer decreased without further treatment 12 weeks after transplant.
Tamura
T
T
First Department of Internal Medicine, Yokohama City University School of Medicine, Japan.
Kanamori
H
H
Yamazaki
E
E
Ohtsuka
M
M
Hataoka
K
K
Maeda
K
K
Okamoto
R
R
Tanabe
J
J
Fujita
H
H
Hashimoto
Y
Y
D000328:Adult; D000744:Anemia, Hemolytic, Autoimmune / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D016572:Cyclosporine / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D015994:Incidence; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D014184:Transplantation, Homologous
D016572:Cyclosporine; D011239:Prednisolone; D008727:Methotrexate